Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?

16 Dec 2021

Abstract excerpt

Introduction Carcinomas with defects in the homologous recombination (HR) pathway are sensitive to PARP inhibitors (PARPi). A robust method to identify HR-deficient (HRD) carcinomas is therefore of utmost clinical importance. Currently, available DNA-based HRD tests either scan HR-related genes such as BRCA1 and BRCA2 for the presence of pathogenic variants or identify HRD-related genomic scars or mutational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34913794
DOI: 10.1080/14737159.2022.2020102

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?PMID 34913794Read ↗

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA RepairSemantic proximity Read ↗

Biomarkers for Homologous Recombination Deficiency in CancerSemantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnosticsSemantic proximity Read ↗

Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.Semantic proximity Read ↗

Whole Genome Analysis Identifies Homologous Recombination Deficiency in Cancers with BRCA1/2 Wild-Type and BRCA1/2 Structural VariantsSemantic proximity Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer CohortSemantic proximity Read ↗

Biomarkers for Homologous Recombination Deficiency in CancerSemantic proximity Read ↗

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissueSemantic proximity Read ↗

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.